Early dementia detection: which startup is ahead?

Which startups really belong in the early dementia detection race?

About 11 private companies belong in the early dementia detection race today, and seven are serious near-term contenders.

We include startups that do at least one of three jobs: detect cognitive impairment, identify biological evidence linked to Alzheimer’s disease, or predict whether mild cognitive impairment will progress toward dementia. We exclude general brain-training apps, academic projects without a commercial product, companies focused mainly on monitoring diagnosed patients, and large diagnostics groups such as Roche, Fujirebio, Abbott, Siemens Healthineers and Beckman Coulter.

The field looks crowded until we separate those three jobs. BrainCheck, Neurotrack and Linus Health help clinicians find cognitive impairment sooner. C2N Diagnostics and ALZpath focus on Alzheimer’s biology in blood. Darmiyan and ADmit Therapeutics estimate progression risk among people who already have mild cognitive impairment. RetiSpec, ViewMind and Altoida are developing earlier retinal, eye-movement or digital markers, but their clinical adoption remains limited.

Funding totals are approximate because private databases often miss grants, strategic support and undisclosed rounds. C2N’s publicly tracked venture funding, for example, understates the grants and philanthropic support behind its research. ALZpath has never disclosed a reliable cumulative total. The table gives the best public range without pretending that every dollar is known.

Startup	What it does	Main approach	Approximate cumulative funding
Linus Health	Finds cognitive impairment and tracks decline	Tablet assessments and digital biomarkers	$65M
Neurotrack	Screens for cognitive impairment in primary and home care	Short digital cognitive tests	$58M
BrainCheck	Assesses MCI, dementia and other cognitive problems	Digital testing and care workflows	$50M
C2N Diagnostics	Detects amyloid pathology linked to Alzheimer’s disease	Blood pTau217 and amyloid biomarkers	At least $35M publicly tracked
Altoida	Looks for subtle cognitive and motor changes	Smartphone and augmented-reality tasks	$22M
RetiSpec	Looks for retinal patterns linked to Alzheimer’s disease	AI analysis of hyperspectral retinal images	$17M
ADmit Therapeutics	Predicts progression from MCI to Alzheimer’s dementia	Blood epigenetics, genetics and cognitive data	$13M
ViewMind	Detects cognitive change through visual behavior	Eye movement, pupil response and digital tasks	$11M
Darmiyan	Predicts progression from amnestic MCI to Alzheimer’s dementia	AI analysis of conventional brain MRI	$10M
SYNAPS Dx	Supports Alzheimer’s diagnosis in people with dementia	Skin biopsy and laboratory analysis	$10M
ALZpath	Supplies pTau217 technology for Alzheimer’s blood tests	Proprietary antibody licensed to diagnostics companies	Undisclosed

Is one early dementia detection startup clearly ahead today?

C2N Diagnostics is ahead in early dementia detection today, and ALZpath is the only startup close enough to challenge it.

C2N leads because PrecivityAD2 already combines strong clinical validation, nationwide US availability and a path toward both FDA authorization and insurance coverage. The test identifies likely brain amyloid pathology in symptomatic patients, which is more useful for Alzheimer’s treatment decisions than a general indication of poor cognitive performance. C2N has also moved beyond one specialist laboratory channel and expanded access outside the United States.

ALZpath is taking a different route. Its proprietary pTau217 antibody is being used by Abbott, Beckman Coulter, Roche, Siemens Healthineers, Alamar Biosciences, Bio-Techne and Quanterix. Roche has already received a European CE mark for an assay built around the technology. That partner network could eventually put ALZpath inside more hospital laboratories than C2N can reach through its own testing service.

The rest of the field sits a clear step below those two. BrainCheck leads disclosed digital-assessment volume. Neurotrack has some of the strongest real-world primary-care results. Linus Health has the deepest publication base among digital players. Darmiyan owns the clearest completed FDA milestone for predicting progression from amnestic mild cognitive impairment. Each leads a narrower lane. C2N and ALZpath are shaping the core Alzheimer’s blood-testing market.

If you want more recent data on this point, please see our latest digital health market report.

Which startup has the most useful early dementia test in clinical care?

C2N Diagnostics currently has the most useful startup-built test for an Alzheimer’s evaluation in clinical care.

PrecivityAD2 combines the percentage of phosphorylated tau at position 217 with the amyloid-beta 42/40 ratio. The result estimates whether a symptomatic patient probably has amyloid pathology in the brain. That gives clinicians information about the likely cause of cognitive symptoms. A cognitive screen mainly shows that a problem may exist.

A large JAMA study tested PrecivityAD2 in primary-care and memory-clinic populations. The test classified amyloid status correctly in more than 90% of patients when compared with amyloid PET or cerebrospinal-fluid testing. Physicians also changed diagnostic plans after receiving the blood result and reported greater confidence in their decisions. Those workflow effects make the evidence more useful than an accuracy figure from a small research cohort.

ALZpath’s pTau217 technology can produce similarly strong biological information, although ALZpath usually reaches patients through partner assays. Darmiyan’s BrainSee answers a valuable prognosis question, but only after a patient has already been diagnosed with amnestic mild cognitive impairment. BrainCheck, Neurotrack and Linus Health fit much earlier into primary care, yet a positive digital assessment still requires follow-up to determine the cause.

Which early dementia detection startup has the strongest clinical evidence?

C2N has the strongest clinical evidence in early dementia detection today.

C2N’s advantage comes from the range of questions its studies have answered. PrecivityAD2 has been compared with amyloid PET and cerebrospinal fluid, tested in primary care and specialist settings, validated outside the original development work, and studied for its effect on physician decisions. The studies cover test performance, real patients and the decisions doctors make afterward.

ALZpath’s pTau217 assay has also performed strongly. A JAMA Neurology study covering 786 participants across three cohorts reported sensitivity ranging from about 85% to 98%, depending on the cohort and cutoff, with specificity of roughly 75% to 85%. A two-threshold approach produced positive and negative agreement around 92% to 96%, leaving an uncertain middle group for additional testing. That design is practical because it can clear many obvious cases without forcing one cutoff to handle every patient.

The scale of research around ALZpath has grown sharply lately. The company counted 29 presentations using its antibody at AD/PD 2026 and 86 at AAIC 2026. Those 115 presentations are company-reported and vary in importance, but the total shows that many independent groups are now testing the same core technology across different populations and laboratory platforms.

The digital companies have credible evidence for cognitive screening, although comparison is harder because their products measure different tasks and outcomes. Linus Health points to more than 150 peer-reviewed publications. BrainCheck reports strong dementia and MCI classification in published studies. Neurotrack has promising sensitivity and specificity data, plus unusually concrete implementation results. None currently matches the biological validation and clinical decision evidence assembled around C2N and ALZpath.

Which early dementia startup is furthest through regulation?

Darmiyan leads early dementia regulation today because BrainSee already has FDA De Novo authorization.

The FDA granted De Novo marketing authorization to Darmiyan’s BrainSee in January 2024. BrainSee helps clinicians estimate whether people aged 55 to 95 with amnestic mild cognitive impairment are likely to progress to clinical Alzheimer’s dementia within five years. The FDA describes the software as an adjunctive tool, so doctors must interpret the result alongside the rest of the clinical assessment.

C2N submitted PrecivityAD2 to the FDA in October 2025 and the application is currently under review. PrecivityAD2 can serve symptomatic patients being evaluated for Alzheimer’s disease or dementia. BrainSee starts with the smaller group already diagnosed with amnestic MCI. The first FDA-cleared Alzheimer’s blood test still belongs to Fujirebio, an established diagnostics company, which means no startup has yet secured that particular lead.

ADmit Therapeutics reached an important European milestone when MAP-AD received a CE mark under the In Vitro Diagnostic Regulation in September 2025. Roche then received a European CE mark for its ALZpath-powered Elecsys pTau217 assay in 2026. ALZpath gains regulatory reach through Roche in this case. Darmiyan and ADmit own their authorized products directly.

The regulatory order is clear. Darmiyan leads on completed startup-owned FDA authorization. C2N has the strongest pending US case. ALZpath has the widest indirect route through major diagnostics partners.

Which early dementia detection startup has the strongest commercial traction?

BrainCheck has the largest disclosed customer usage in early dementia detection, and C2N has the strongest Alzheimer’s-specific diagnostic business.

BrainCheck says clinicians have completed more than 640,000 assessments across over 500 healthcare organizations. The company also added more than 150 practices and health systems during 2025, meaning roughly three in ten of its current sites joined in a single year. Private companies rarely publish audited usage data, but those figures still show repeatable deployment well beyond a pilot program.

Neurotrack discloses less total volume and gives more detail about individual healthcare systems. Desert Oasis Healthcare screens about 20,000 patients a year with Neurotrack and reported a 35% net increase in new dementia diagnoses after deployment. In a separate Signify Health program, 3.1% of assessed members received a recommendation for a cognitive care plan, compared with 0.6% under the previous Mini-Cog workflow. That fivefold difference suggests the software is changing what clinicians do after screening.

C2N has not published a comparable cumulative test count. Its strongest progress has come in payment and clinical access. PrecivityAD2 is available across the United States, Mayo Clinic Laboratories supports access, and Anthem has announced coverage for eligible members beginning later this year. That coverage decision could expose the test to a health plan serving tens of millions of people, although announced eligibility should not be confused with actual testing volume.

ALZpath has signed the strongest licensing deals in the field, yet public data gives no assay royalties, test counts or partner revenue. BrainCheck keeps the current volume lead. C2N leads the commercial race for an Alzheimer’s-specific diagnostic.

Which early dementia detection startup is growing fastest now?

ALZpath is growing fastest today by placing its pTau217 technology across major laboratory platforms.

ALZpath’s expansion comes from a series of licensing agreements. Roche and Beckman Coulter signed first, Siemens Healthineers followed, and Abbott joined more recently. The company now supplies or supports pTau217 work across seven major diagnostics and life-science platforms. ALZpath also counted 115 presentations using the antibody across two major 2026 meetings. A biomarker appearing across seven platforms and that many research presentations has moved far beyond one company’s development program.

C2N’s recent sequence is more directly commercial. The company gained a demanding New York State laboratory permit, entered South Korea, expanded across Latin America and the Caribbean, and secured an Anthem coverage decision. These moves address laboratory access, geographic reach and payment within the same period.

BrainCheck also grew quickly. More than 150 sites joined during 2025, an increase equal to roughly 30% of its current disclosed base, and a new $13 million round gives the company more capital to expand cognitive-care workflows. Linus Health has continued publishing and adding distribution relationships. ADmit has moved from validation into European commercialization. None has matched the recent pace of ALZpath and C2N.

If you want more recent data on this point, please see our latest digital health market report.

Which startup can detect Alzheimer’s disease earliest?

C2N and ALZpath can flag Alzheimer’s biology earlier than the other startups, but doctors should not routinely use these blood tests to screen healthy adults.

Blood pTau217 can become abnormal before dementia is obvious in everyday life. A pooled analysis of 2,684 cognitively unimpaired older adults found that people in the highest pTau217 group had an estimated 38% risk of developing cognitive impairment within five years and a 78% risk within ten years. That makes pTau217 valuable for risk stratification and research years before a conventional dementia diagnosis.

Clinical use remains narrower. Current Alzheimer’s Association guidance focuses on blood biomarkers for cognitively impaired patients being assessed in specialist care. The first FDA-cleared blood test also covers adults aged 55 and older who already have signs or symptoms. A high biomarker result in a healthy person does not guarantee future dementia, and widespread population screening still lacks clear treatment and follow-up rules.

Digital tools can enter care earlier in a practical sense. BrainCheck, Neurotrack and Linus Health can be used during routine visits to uncover cognitive problems that nobody has formally documented. Their tests reveal changes in performance. Clinicians still need blood testing, imaging or another evaluation to explain a positive result.

Darmiyan and ADmit operate later because their products start with mild cognitive impairment and estimate progression. RetiSpec, ViewMind and Altoida aim to pick up subtler preclinical patterns, but their evidence and market use remain too limited for us to place them ahead of blood pTau217.

Which early dementia detection products are mature enough to scale?

C2N, BrainCheck, Neurotrack and Linus Health can already handle meaningful deployment today.

C2N has a functioning national laboratory workflow. PrecivityAD2 can be ordered across the United States, and C2N has built sample collection, shipping, quality control and reporting around the test. Earlier expansion included more than 700 patient service centers and thousands of mobile phlebotomists. Recent partnerships have extended the same portfolio into additional countries.

BrainCheck has the clearest software scale. As noted above, more than 640,000 assessments have been completed across over 500 organizations. Once a clinic has integrated the workflow and trained staff, the cost of adding another assessment is modest. Neurotrack has shown that a single provider can screen around 20,000 patients each year, and Linus Health offers short tablet-based assessments backed by a large research base and distribution partnerships.

ALZpath could ultimately scale further than all four. The company avoids building its own worldwide laboratory network by placing its antibody inside major automated analyzers. A successful assay can then travel through an installed base, existing sales teams and familiar hospital procurement channels.

Darmiyan has cleared the regulatory hurdle, yet routine BrainSee volume remains unclear. ADmit has started European commercialization after its CE mark. RetiSpec says its system is deployed across more than 20 global sites, which is meaningful validation progress, though still far from broad clinical use. ViewMind and Altoida remain closer to research and limited deployment.

Which early dementia startup performs best on accuracy and clinical usefulness?

C2N performs best today because PrecivityAD2 is accurate and gives doctors an answer they can act on during an Alzheimer’s evaluation.

Accuracy figures across this field need careful interpretation. C2N and ALZpath estimate amyloid pathology. BrainCheck and Neurotrack identify cognitive impairment. Darmiyan predicts five-year progression among people with amnestic MCI. A 90% result in one group may answer a completely different clinical question from a 90% result in another.

PrecivityAD2 has exceeded 90% classification accuracy against amyloid PET or cerebrospinal fluid in major clinical studies. ALZpath’s pTau217 assay has produced similarly strong performance across several cohorts and platforms. C2N gets the edge because its evidence follows one complete commercial test through real clinical workflows. ALZpath’s data is spread across an antibody, research assays and partner products.

BrainCheck reports about 88% sensitivity and 94% specificity for dementia in one published dataset, with lower performance for MCI. Neurotrack has reported about 94% sensitivity and 90% specificity for selected combinations of its tests, though some of its strongest results come from smaller samples. BrainSee reports roughly 90% accuracy in a 411-case longitudinal dataset and benefits from FDA review, but the eligible population is narrow.

Startup or product	What the test predicts	Best reported performance	How we read the evidence
C2N PrecivityAD2	Amyloid pathology linked to Alzheimer’s disease	More than 90% classification accuracy in major studies	Strongest mix of accuracy, independent validation and clinical usefulness
ALZpath pTau217	Amyloid pathology linked to Alzheimer’s disease	About 85% to 98% sensitivity and 75% to 85% specificity across cohorts	Very strong biomarker evidence across a growing number of platforms
BrainCheck	Dementia or mild cognitive impairment	About 88% sensitivity and 94% specificity for dementia in one dataset	Strong digital screen with large disclosed use; the result still needs a cause
Neurotrack	Cognitive impairment	About 94% sensitivity and 90% specificity for selected test combinations	Promising results plus strong implementation evidence; some datasets remain small
Darmiyan BrainSee	Five-year progression from amnestic MCI to Alzheimer’s dementia	Roughly 90% accuracy in a 411-case dataset	Credible specialized prognosis tool with FDA review behind it

If you want more recent data on this point, please see our latest digital health market report.

Which early dementia detection product is cheapest to deploy?

BrainCheck, Neurotrack and Linus Health offer the cheapest route to broad screening, and automated blood tests give better value when doctors need an Alzheimer’s-specific answer.

Digital testing requires a tablet or computer, a short appointment and staff time. Neurotrack says its workflow saves about ten minutes per encounter compared with paper testing. Linus Health offers assessments that can take roughly three to eight minutes. BrainCheck can combine screening, deeper assessment and care planning inside one platform. Those economics suit annual wellness visits and large primary-care populations.

A positive digital result can still trigger several follow-up steps. The patient may need a blood test, imaging, specialist review or a lumbar puncture before the cause becomes clear. A cheap first test can still lead to an expensive diagnostic journey.

C2N requires a blood draw, shipping and specialized laboratory analysis. The direct cost is higher, but PrecivityAD2 can reduce reliance on amyloid PET or cerebrospinal-fluid testing for appropriately selected patients. ALZpath has the best chance of becoming cheap at large scale because partner assays can run on automated analyzers already installed in hospital laboratories.

Darmiyan can add value to an MRI that a patient is already receiving. Its economics become less attractive when a new MRI is ordered solely for BrainSee. SYNAPS Dx has the heaviest workflow among the startups studied here because it requires a skin biopsy and a laboratory turnaround measured in weeks.

Which early dementia startup has won the strongest customers and partners?

ALZpath has won the strongest partner roster in early dementia detection.

ALZpath has convinced several competing diagnostics leaders to build around the same pTau217 antibody. Abbott, Beckman Coulter, Roche and Siemens Healthineers each have global regulatory teams, established analyzers and direct access to hospital laboratories. Bio-Techne, Alamar Biosciences and Quanterix expand the research and specialty-testing side. As seen above, the repetition across seven platforms gives ALZpath far more credibility than a single development agreement would.

C2N’s partnerships cover the full route from clinician to patient. Mayo Clinic Laboratories helps with ordering and distribution, and international partners add local access in South Korea, Latin America and the Caribbean. These relationships support a finished product that doctors can use now.

Neurotrack has the strongest named customer evidence among digital players. Desert Oasis discloses annual screening volume and a measurable change in dementia diagnoses. Signify Health has published a clear difference in care-plan recommendations. BrainCheck reports a broader customer base, though it gives less detail about how deeply each organization uses the platform. Linus Health has credible research and distribution partners, but public utilization data remains thin.

Which early dementia detection startup has the hardest advantage to copy?

ALZpath owns the hardest single asset to copy in early dementia detection.

ALZpath’s proprietary pTau217 antibody now sits inside research programs and product development across several diagnostics companies. A challenger would need to match its analytical performance, build a comparable body of studies, persuade manufacturers to switch and repeat platform-specific regulatory work. Every additional partner assay raises that barrier.

C2N’s advantage comes from the full chain around PrecivityAD2: mass-spectrometry expertise, proprietary measurements, algorithms, clinically characterized datasets, laboratory operations, ordering access and payer work. A rival can develop another pTau217 test. Recreating the same clinical trust and commercial workflow requires much more time.

Darmiyan has a narrower regulatory head start. BrainSee’s De Novo authorization creates a benchmark for MRI-based progression software, although larger imaging companies could enter the category. ADmit’s combination of mitochondrial DNA methylation, ApoE, age and cognitive data may become defensible if larger prospective studies confirm its performance.

Digital screening companies rely on normative data, workflow integration, publications and customer habits. BrainCheck’s installed use and Linus Health’s research base have value, but large healthcare-software companies can reproduce many digital tasks. Their strongest protection comes from becoming embedded in routine care before bigger platforms decide to compete.

If you want more recent data on this point, please see our latest digital health market report.

Is the best-funded early dementia startup actually ahead?

No: Linus Health, Neurotrack and BrainCheck raised more money, yet C2N and ALZpath have more influence on where the market is going.

Linus Health, Neurotrack and BrainCheck have raised the largest disclosed totals, at roughly $50 million to $65 million each. That money has helped them build software platforms, clinical evidence and distribution. BrainCheck has converted its funding into the clearest disclosed usage base. Neurotrack has produced strong health-system results, and Linus has built a deep publication record.

C2N has at least $35 million in publicly tracked funding, with additional support that is difficult to total. The company has built a national blood test and secured major payer progress. As seen above, Darmiyan reached De Novo authorization with roughly $10 million in disclosed capital. ADmit reached a European CE mark with about $13 million. Those outcomes show why raw funding is a poor proxy for leadership in diagnostics.

ALZpath is the hardest company to judge because its cumulative financing is undisclosed. Its licensing model may also require less capital than operating a laboratory, selling software into hundreds of clinics or running a proprietary analyzer network. From the public evidence, ALZpath looks highly capital-efficient, although no reliable ratio can be calculated.

Funding still affects the next stage. C2N needs enough capital to handle regulatory work, reimbursement and growing test volume. Digital players need sales and implementation teams. RetiSpec and ViewMind need larger validation programs. We give more weight to what each startup has already built than to the size of its last round.

Which startups are actually ahead in early dementia detection?

C2N Diagnostics is the startup to beat in early dementia detection today.

C2N earns first place because PrecivityAD2 is the strongest complete startup-owned product in the field. As seen above, the test is clinically validated, commercially available across the United States, under FDA review and moving into insurance coverage. C2N has also shown that it can expand internationally without losing focus on the central clinical use case: helping doctors evaluate symptomatic patients for Alzheimer’s pathology.

ALZpath ranks second and could still become the larger company in practice. Licensed assays give its pTau217 technology a credible route to higher testing volume than C2N could process directly. We currently place C2N around 10% ahead because C2N controls the finished product and the patient workflow today.

BrainCheck ranks third through sheer deployment. As pointed out above, more than 640,000 assessments across over 500 organizations place it well ahead of most digital rivals on visible use. Neurotrack follows because its named deployments show stronger effects on diagnosis and care planning. Linus Health has excellent scientific depth, but the company publishes less routine usage data.

Darmiyan comes next because its FDA authorization is a rare and difficult achievement. ADmit follows with a regulated European prognosis test. SYNAPS Dx has a commercial product, although its biopsy workflow and later-stage use case limit front-line scale. RetiSpec, ViewMind and Altoida remain promising technologies with insufficient commercial evidence for a higher ranking.

Three developments could change this ranking. An FDA decision for PrecivityAD2 would widen C2N’s lead. Broad approval and reimbursement for ALZpath-powered partner assays could put ALZpath first. A digital startup could also move up by proving that systematic screening leads to more confirmed diagnoses, treatment starts and better outcomes across several health systems.

Rank	Startup	Leader index	Why it ranks here
1	C2N Diagnostics	100	Strongest complete Alzheimer’s blood test, national availability and the clearest path into routine care
2	ALZpath	90	Best chance of becoming the common pTau217 infrastructure behind large laboratory platforms
3	BrainCheck	72	Clear disclosed deployment leader among digital cognitive-assessment startups
4	Neurotrack	68	Strong primary-care implementation evidence and measurable effects on diagnosis and care planning
5	Linus Health	63	Deep scientific base and credible distribution, with less public evidence on routine usage
6	Darmiyan	56	Strongest completed startup-owned FDA milestone, limited by a narrow eligible population and unclear commercial volume
7	ADmit Therapeutics	47	Regulated European prognosis test with differentiated science, still early in commercialization
8	SYNAPS Dx	40	Commercially available test with a slower and less scalable biopsy workflow
9	RetiSpec	35	Promising retinal platform, strong investors and more than 20 validation sites, with little broad clinical adoption so far
10	ViewMind	31	Interesting eye-tracking approach and active validation, with limited Alzheimer’s-specific commercial evidence
11	Altoida	27	Plausible digital biomarkers, but weaker current regulatory and commercial momentum than the rest of the field

If you want more recent data on this point, please see our latest digital health market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.